Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate to severe psoriasis: Feasibility study using 18F-fluorodeoxyglucose positron emission tomography-computed tomography

Psoriasis may be associated with metabolic syndrome and an increased risk of cardiovascular disease.; Patients with psoriasis had increased hepatic, splenic, and arterial inflammation, which decreased with ustekinumab therapy.; Ustekinumab treatment was significantly associated with decreased systemic and vascular inflammation related to metabolic syndrome and cardiovascular disease among patients with psoriasis.